Bausch + Lomb (NYSE:BLCO) versus Sonic Healthcare (OTCMKTS:SKHHY) Head-To-Head Contrast

Sonic Healthcare (OTCMKTS:SKHHY) and Bausch + Lomb (NYSE:BLCO) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability and risk.

Risk and Volatility

Sonic Healthcare has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Sonic Healthcare and Bausch + Lomb, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonic Healthcare	0	0	1	0	3.00
Bausch + Lomb	1	7	3	0	2.18

Sonic Healthcare currently has a consensus price target of $30.15, indicating a potential upside of 101.67%. Bausch + Lomb has a consensus price target of $15.56, indicating a potential upside of 1.50%. Given Sonic Healthcare’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Sonic Healthcare is more favorable than Bausch + Lomb.

Earnings and Valuation

This table compares Sonic Healthcare and Bausch + Lomb”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonic Healthcare	$5.94 billion	1.24	$337.11 million	N/A	N/A
Bausch + Lomb	$4.79 billion	1.13	-$317.00 million	($0.78)	-19.65

Sonic Healthcare has higher revenue and earnings than Bausch + Lomb.

Institutional and Insider Ownership

0.0% of Sonic Healthcare shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 0.2% of Bausch + Lomb shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Sonic Healthcare and Bausch + Lomb’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sonic Healthcare	N/A	N/A	N/A
Bausch + Lomb	-5.58%	2.33%	1.12%

Summary

Sonic Healthcare beats Bausch + Lomb on 7 of the 12 factors compared between the two stocks.

About Sonic Healthcare

Sonic Healthcare Limited offers medical diagnostic services to medical practitioners, hospitals, community health services, and their collective patients. The company provides laboratory medicine/pathology testing services, such as biochemistry, cytopathology, genetics, haematology, histopathology, immunoserology, microbiology, molecular pathology, prenatal testing, toxicology, and ancillary functions; and radiology services, including magnetic resonance imaging, computed tomography (CT), ultrasound, X-ray, mammography, nuclear medicine, PET CT, interventional procedures, and bone mineral densitometry. It offers primary care medical services comprising general practice clinics, occupational health services, skin cancer clinics, after-hours general practice services, general practice IT solutions, and community-based healthcare services. The company operates in Australia, the United Kingdom, Ireland, the United States, Germany, Switzerland, New Zealand, Belgium, and internationally. Sonic Healthcare Limited was incorporated in 1934 and is headquartered in Sydney, Australia.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.